6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT
Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
Investor Presentation
Director Elections and Amended 2020 Stock Plan Approved at Clene Inc.
Material Contracts, Financial Results
Announces $7 Million Underwritten Offering of Common Stock
After Successful FDA Meeting, Filing Accelerated Approval NDA for ALS
Annual Report to Security Holders
Subaward Agreement with New York University Executed by Clene Inc.
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Specialized Disclosure Report
Correspondence
Submission Upload